GLP1R and cardiovascular disorder: As per International diabetes federation, global prevalence of diabetes mellitus among adults was 10.5% in 2021 and this number will surge by 783 million by 2045.1 It is imperative to manage the disease effectively for the prevention of the long-term complications of T2D, including cardiovascular diseases, nephropathy, and retinopathy.2 Insulin degludec/liraglutide (IDegLira) is a novel fixed-ratio combination of a long-acting basal insulin (insulin degludec) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (as liraglutide).